MS treatment: What is Plan B?


Comment by Dr. Paul Steven Giacomini
NeuroSens survey on sequencing

The year 2013 was the twentieth anniversary of the first published trial of a disease-modifying therapy (DMT) in multiple sclerosis, an occasion marked by the arrival of two new oral agents in an expanding armamentarium of MS therapies. Teriflunomide got the green light in Canada and Europe (previously approved in the U.S.); and dimethyl fumarate (DMF) was approved in Canada and the U.S. (but is still pending in Europe).

It takes 30 seconds

Recommend to a Colleague Go back to home page